Prime Medicine (PRME) Current Deferred Revenue (2024 - 2026)

Prime Medicine's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $7.3 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 10.88% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 10.88% YoY) and the FY2025 annual result came in at $7.8 million, up 10.32% from the prior year.
• Current Deferred Revenue was $7.3 million for Q1 2026 at Prime Medicine, down from $7.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $9.3 million in Q3 2024 and bottomed at $7.0 million in Q3 2025.
• A 3-year average of $7.9 million and a median of $7.8 million in 2025 frame the typical range for Current Deferred Revenue.
• Peak annual rise in Current Deferred Revenue reached 10.32% in 2025, while the deepest fall reached 25.1% in 2025.
• Prime Medicine's Current Deferred Revenue stood at $7.1 million in 2024, then climbed by 10.32% to $7.8 million in 2025, then dropped by 6.44% to $7.3 million in 2026.
• Business Quant data shows PRME's Current Deferred Revenue at $7.3 million in Q1 2026, $7.8 million in Q4 2025, and $7.0 million in Q3 2025.